|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-24
|
|
pubmed:abstractText |
Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:AnsariRafatR,
pubmed-author:BecharNaftaliN,
pubmed-author:BedanoPabloP,
pubmed-author:BhatiaSumeetS,
pubmed-author:EinhornLawrenceL,
pubmed-author:GovindanRamaswamyR,
pubmed-author:HannaNasserN,
pubmed-author:JalalShadiaS,
pubmed-author:KoneruKarunaK,
pubmed-author:SchneiderBryanB,
pubmed-author:WuJingweiJ,
pubmed-author:YuMenggangM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2008-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21102263-Adult,
pubmed-meshheading:21102263-Aged,
pubmed-meshheading:21102263-Aged, 80 and over,
pubmed-meshheading:21102263-Antibodies, Monoclonal,
pubmed-meshheading:21102263-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21102263-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21102263-Feasibility Studies,
pubmed-meshheading:21102263-Female,
pubmed-meshheading:21102263-Genotype,
pubmed-meshheading:21102263-Humans,
pubmed-meshheading:21102263-Lung Neoplasms,
pubmed-meshheading:21102263-Male,
pubmed-meshheading:21102263-Middle Aged,
pubmed-meshheading:21102263-Neoplasm Recurrence, Local,
pubmed-meshheading:21102263-Paclitaxel,
pubmed-meshheading:21102263-Small Cell Lung Carcinoma,
pubmed-meshheading:21102263-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
|
|
pubmed:affiliation |
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA. sjalal@iupui.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
